Clinical Trial

A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The overall objective of the trial is to evaluate the effect of the triple therapy consisting of bempedoic acid (BA), ezetimibe (EZE), and high-intensity atorvastatin or rosuvastatin on changes in coronary plaque burden and plaque morphology in patients with coronary atherosclerosis without significant obstructive coronary artery disease and without prior history of an ischemic vascular event.
Protocol Amendment History 1 change
notable Trial sites expanded: 0 -> 12 locations 2026-08-08
Trial Details
NCT Number NCT07474649
Lead Sponsor Daiichi Sankyo
Conditions Coronary Atherosclerosis, Mixed Dyslipidemia, Hypercholesterolemia
Enrollment 103 participants
Start Date 2026-08-15
Primary Completion 2028-06-01 (estimated)
Study Completion 2028-10-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-07